Impact of SARS‐CoV‐2 infection and COVID‐19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain

Abstract

AbstractBackground and purposeThe purpose was to describe the risk of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, hospitalization for coronavirus disease 2019 (COVID‐19) and related death and to assess the impact of the pandemic in the survival of amyotrophic lateral sclerosis (ALS) patients.MethodsThe risk of SARS‐CoV‐2 infection, hospitalization for COVID‐19 and related death was assessed in ALS patients alive between March 2020 and July 2022. To evaluate its impact in the overall survival of ALS patients, the survival of patients who died before and during the pandemic was compared.ResultsAmongst 263 ALS patients alive during the pandemic, 62 got infected during the study period (infection rate 14.34 per 100 person‐years). Most infections (68%) occurred during the sixth wave (November 2021 to January 2022) and most patients (67%) were vaccinated at the time of infection. The hospitalization rate due to COVID‐19 was 4.16 per 100 person‐years. The multivariable model confirmed non‐invasive ventilation (NIV) use prior to infection as a risk factor for hospitalization (odds ratio [OR] = 7.96, p = 0.003) and COVID‐19 vaccination as a protective factor (OR = 0.093, p = 0.025) independent of age, sex and gastrostomy. Within 30 days after infection, 7% of non‐ventilated patients started NIV and five patients (8.06%) died, of whom four were previously ventilated. The median survival of ALS patients was similar before and during the pandemic and no effect was found in the Cox regression model (hazard ratio 1.02, p = 0.89).ConclusionsThis study shows a high risk of severe COVID‐19 amongst ALS patients requiring NIV. Nevertheless, the pandemic showed no impact in the overall survival of ALS patients, probably due to a high vaccination rate and an adequate access to healthcare resources.